Your browser doesn't support javascript.
loading
α-Ketoglutarate links p53 to cell fate during tumour suppression.
Morris, John P; Yashinskie, Jossie J; Koche, Richard; Chandwani, Rohit; Tian, Sha; Chen, Chi-Chao; Baslan, Timour; Marinkovic, Zoran S; Sánchez-Rivera, Francisco J; Leach, Steven D; Carmona-Fontaine, Carlos; Thompson, Craig B; Finley, Lydia W S; Lowe, Scott W.
Afiliación
  • Morris JP; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Yashinskie JJ; Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Koche R; Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Chandwani R; Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY, USA.
  • Tian S; Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Chen CC; Department of Surgery, Weill Cornell Medical College, New York, NY, USA.
  • Baslan T; Rubinstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Marinkovic ZS; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Sánchez-Rivera FJ; Department of Cell and Developmental Biology, Weill Cornell Medical College, New York, NY, USA.
  • Leach SD; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Carmona-Fontaine C; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Thompson CB; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Finley LWS; Department of Biology, Center for Genomics and Systems Biology, New York University, New York, NY, USA.
  • Lowe SW; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nature ; 573(7775): 595-599, 2019 09.
Article en En | MEDLINE | ID: mdl-31534224
ABSTRACT
The tumour suppressor TP53 is mutated in the majority of human cancers, and in over 70% of pancreatic ductal adenocarcinoma (PDAC)1,2. Wild-type p53 accumulates in response to cellular stress, and regulates gene expression to alter cell fate and prevent tumour development2. Wild-type p53 is also known to modulate cellular metabolic pathways3, although p53-dependent metabolic alterations that constrain cancer progression remain poorly understood. Here we find that p53 remodels cancer-cell metabolism to enforce changes in chromatin and gene expression that favour a premalignant cell fate. Restoring p53 function in cancer cells derived from KRAS-mutant mouse models of PDAC leads to the accumulation of α-ketoglutarate (αKG, also known as 2-oxoglutarate), a metabolite that also serves as an obligate substrate for a subset of chromatin-modifying enzymes. p53 induces transcriptional programs that are characteristic of premalignant differentiation, and this effect can be partially recapitulated by the addition of cell-permeable αKG. Increased levels of the αKG-dependent chromatin modification 5-hydroxymethylcytosine (5hmC) accompany the tumour-cell differentiation that is triggered by p53, whereas decreased 5hmC characterizes the transition from premalignant to de-differentiated malignant lesions that is associated with mutations in Trp53. Enforcing the accumulation of αKG in p53-deficient PDAC cells through the inhibition of oxoglutarate dehydrogenase-an enzyme of the tricarboxylic acid cycle-specifically results in increased 5hmC, tumour-cell differentiation and decreased tumour-cell fitness. Conversely, increasing the intracellular levels of succinate (a competitive inhibitor of αKG-dependent dioxygenases) blunts p53-driven tumour suppression. These data suggest that αKG is an effector of p53-mediated tumour suppression, and that the accumulation of αKG in p53-deficient tumours can drive tumour-cell differentiation and antagonize malignant progression.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Diferenciación Celular / Proteína p53 Supresora de Tumor / Carcinoma Ductal Pancreático / Ácidos Cetoglutáricos Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Nature Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Diferenciación Celular / Proteína p53 Supresora de Tumor / Carcinoma Ductal Pancreático / Ácidos Cetoglutáricos Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Nature Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos
...